The November DCI Seminar Series will be held Wednesday, Nov. 15, at the Great Hall located in the Trent Semans Center. David Porter, MD, the director, since 1996, of Allogeneic Bone Marrow Transplantation and Immunotherapy at the University of Pennsylvania Medical Center, will present “Using Chimeric Antigen Receptor Gene Modified T cells to Treat Leukemia.”
Porter, the Jodi Fisher Horowitz Professor in Leukemia Care Excellence at University of Pennsylvania School of Medicine, has been on faculty at the University of Pennsylvania School of Medicine since 1996. He works in the Hematology-Oncology and BMT Clinic three days per week and rounds at the University of Pennsylvania BMT/Leukemia service three months per year.
Porter is on the Chronic Leukemia Working Committee and the Graft-vs-Host Disease/Immune Reconstitution Working Committee of the Center for International Blood Marrow Transplant Registry. He is also a member of the American Soceity of Clinical Oncology, the American Society of Hematology, the American Society of Blood and Marrow Transplantation, the National Marrow Donor Program's Donor & Patient Safety Monitoring Committee, and the Bone Marrow Transplant Clinical Trials Network's Immune Reconstitution Committee. Additionally Porter serves as ad hoc manuscript reviewer for the Annals of Internal Medicine and ad hoc manuscript reviewer for the journal Blood.
Porter received his MD from Brown University and completed clinical and research fellowships in hematology-oncology at Harvard Medical School and Brigham and Women's Hospital.
Porter's lecture begins at 8:10 a.m. and ends at 9 a.m. His address will be preceded by a hematology-oncology fellow presentation starting at 7:30 a.m. The November DCI Seminar Series is presented by the Duke Cancer Institute Hematologic Malignancies and Cellular Therapies Program. Duke Cancer Institute members are invited to attend. For more information, contact Erin Carr.